Table TDI-24. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2004: the combination of cannabis, opioids, cocaine or other stimulants as primary drug type with a secondary drug – Part (v) All clients with stimulants other than cocaine as primary drug type: numbers reporting the stated drugs as secondary

Country

Opioids

Cocaine

Other stimulants

Hypnotics, sedatives

Hallucinogens

Volatile inhalants

Cannabis

Alcohol

Others

Total

Czech Republic

70

5

48

13

36

29

356

33

5

595

Germany

0

0

0

0

0

14

1406

666

63

2149

Greece

0

4

0

1

5

0

6

0

29

45

Italy

258

311

0

9

116

0

677

236

6

1613

Cyprus

1

1

0

0

1

0

4

0

0

7

Netherlands

0

0

0

0

0

0

114

64

14

192

Slovenia

0

0

0

0

0

0

0

0

0

0

Slovakia

44

11

0

5

22

9

110

42

0

243

Finland

94

1

25

55

0

0

193

91

1

460

United Kingdom

746

922

884

506

96

26

1642

406

34

5262

Bulgaria

2

0

2

0

0

0

2

0

0

6

 

 

 

 

 

 

 

 

 

 

 

Total

1215

1255

959

589

276

78

4510

1538

152

10572

Notes: 

Data on secondary drug use are only collected for all treatment clients and not separately for new treatment clients. 

Opioids include: heroin, methadone, other opioids; cocaine includes: cocaine CIH, crack cocaine; stimulants include: amphetamines, MDMA and derivates, other stimulants. Cannabis can include herbal cannabis or cannabis resin. For each client up to four secondary drugs can be reported.

A number of the clients report using the same drug both as primary and secondary drug, particularly for cannabis. Clients may report using different sub-types of the same substance, as defined in the TDI Protocol for the drugs categories. The greater part of clients using cannabis both as primary and secondary drug comes from Germany.

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Source:

2005 Reitox national reports

Data filter | tditab24e-en.xml